Publications
Detailed Information
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Cited 12 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Issue Date
- 2022-05
- Publisher
- Oxford University Press
- Citation
- Annals of Oncology, Vol.33 No.5, pp.566-568
- ISSN
- 0923-7534
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.